Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Bush

Showing results (661-670 of 673) with videos related to

Pageof 68
Sort By:
Journal of Medicinal Chemistry|May 14, 2015
Discovery of N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), a highly selective, orally bioavailable inhibitor of aurora kinases with activity against multidrug-resistant cancer cell linesStephanie Geuns-Meyer, Victor J Cee, Holly L Deak, et al.
Bioorganic & Medicinal Chemistry Letters|July 7, 2012
Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitorsEmily A Peterson, Alessandro A Boezio, Paul S Andrews, et al.
Blood Advances|October 23, 2020
Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill childrenCaroline Diorio, Pamela A Shaw, Edward Pequignot, et al.
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|December 22, 2025
Proposed Development of a New Staging System for Hearing Loss: Countermeasure 2 of the Hearing Health CollaborativeMatthew L Carlson, Teresa A Zwolan, Matthew L Bush, et al.
BMJ Open|November 15, 2017
Decisional needs assessment of patients with complex care needs in primary care: a participatory systematic mixed studies review protocolMathieu Bujold, Pierre Pluye, France Légaré, et al.
Journal of Medicinal Chemistry|August 6, 2010
Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitorVictor J Cee, Laurie B Schenkel, Brian L Hodous, et al.
BMJ Open|November 28, 2018
Case management in primary care for frequent users of healthcare services with chronic diseases and complex care needs: an implementation and realist evaluation protocolCatherine Hudon, Maud-Christine Chouinard, Kris Aubrey-Bassler, et al.
Nature|February 28, 2020
Epigenetic therapy inhibits metastases by disrupting premetastatic nichesZhihao Lu, Jianling Zou, Shuang Li, et al.
Journal of Medicinal Chemistry|April 1, 2026
Optimization of Covalent 6-Cyanoquinazoline KRAS<sup>G12C</sup> Inhibitors for the Treatment of Solid TumorsJesse P Waldo, Paul J Krawczuk, Christopher B Kelly, et al.
Journal of the National Cancer Institute|August 21, 2003
Body mass index, serum sex hormones, and breast cancer risk in postmenopausal womenT J Key, P N Appleby, G K Reeves, et al.
Pageof 68

Showing results (661-670 of 673) with videos related to

Sort By:
Pageof 68
Journal of Medicinal Chemistry|May 14, 2015
Discovery of N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), a highly selective, orally bioavailable inhibitor of aurora kinases with activity against multidrug-resistant cancer cell linesStephanie Geuns-Meyer, Victor J Cee, Holly L Deak, et al.
Bioorganic & Medicinal Chemistry Letters|July 7, 2012
Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitorsEmily A Peterson, Alessandro A Boezio, Paul S Andrews, et al.
Blood Advances|October 23, 2020
Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill childrenCaroline Diorio, Pamela A Shaw, Edward Pequignot, et al.
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|December 22, 2025
Proposed Development of a New Staging System for Hearing Loss: Countermeasure 2 of the Hearing Health CollaborativeMatthew L Carlson, Teresa A Zwolan, Matthew L Bush, et al.
BMJ Open|November 15, 2017
Decisional needs assessment of patients with complex care needs in primary care: a participatory systematic mixed studies review protocolMathieu Bujold, Pierre Pluye, France Légaré, et al.
Journal of Medicinal Chemistry|August 6, 2010
Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitorVictor J Cee, Laurie B Schenkel, Brian L Hodous, et al.
BMJ Open|November 28, 2018
Case management in primary care for frequent users of healthcare services with chronic diseases and complex care needs: an implementation and realist evaluation protocolCatherine Hudon, Maud-Christine Chouinard, Kris Aubrey-Bassler, et al.
Nature|February 28, 2020
Epigenetic therapy inhibits metastases by disrupting premetastatic nichesZhihao Lu, Jianling Zou, Shuang Li, et al.
Journal of Medicinal Chemistry|April 1, 2026
Optimization of Covalent 6-Cyanoquinazoline KRAS<sup>G12C</sup> Inhibitors for the Treatment of Solid TumorsJesse P Waldo, Paul J Krawczuk, Christopher B Kelly, et al.
Journal of the National Cancer Institute|August 21, 2003
Body mass index, serum sex hormones, and breast cancer risk in postmenopausal womenT J Key, P N Appleby, G K Reeves, et al.
Pageof 68